Novo Nordisk, the manufacturer of Ozempic and Wegovy, has suffered a data breach resulting in the compromise of clinical trial data, including patient and healthcare provider information. The Danish pharmaceutical company reported that the hack involved the unauthorized copying of sensitive data, prompting an ongoing effort to restore affected IT systems. The breach highlights the evolving nature of cyberattacks on pharmaceutical companies, which can have significant downstream effects on the healthcare industry. Specifically, the loss of clinical trial data can impact the development and approval of life-saving medications1. This incident underscores the need for robust cybersecurity measures to protect sensitive information in the pharmaceutical sector, particularly as attackers continue to refine their tactics. The breach's consequences will likely be felt throughout the industry, making it essential for healthcare professionals and organizations to be vigilant about data protection and regulatory compliance.